<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4286">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267227</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0225</org_study_id>
    <nct_id>NCT01267227</nct_id>
  </id_info>
  <brief_title>Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress</brief_title>
  <official_title>Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pterostilbene is one of several stilbenes found in certain berries, particularly
      blueberries, that have demonstrated pre-clinical benefit to cholesterol, blood pressure, and
      oxidative stress. The purpose of this study is to evaluate whether pterostilbene will help
      control cholesterol and blood pressure, as well as improve markers for oxidative stress in
      patients with dyslipidemia meeting inclusion criteria. The investigators also want to look
      at the safety of pterostilbene in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be divided into one of four groups: (1) pterostilbene 50 mg twice daily; (2)
      pterostilbene 125 mg twice daily; (3) pterostilbene 50 mg/grape extract 100 mg twice daily;
      (4) matching placebo twice daily taken either one hour before or two hours after a meal.
      Blood and urine will be collected at enrollment and final study visits. If the patient's low
      density lipoprotein-C (LDL-C) or total cholesterol (TC) is not within the inclusion criteria
      based on enrollment blood drawn, the patient will not be allowed to initiate study
      medication. All study visits will consist of brief clinical examination (including vital
      signs), subjective adverse event reporting, and fasting donated blood and urine for clinical
      laboratory tests. Pill counts will be done to assess compliance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Baseline and 6-8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in baseline triglycerides (TG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6-8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in baseline systolic blood pressure and/or diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Adverse Effects</measure>
    <time_frame>Baseline and 6-8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with adverse effects as a measure of safety</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Blood Pressure</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pterostilbene 125 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pterostilbene 50 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pterostilbene 50 mg/Grape Extract 100 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pterostilbene 50 mg twice daily</intervention_name>
    <description>Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks</description>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Low Dose Combination</arm_group_label>
    <other_name>pTeroPure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo by mouth twice daily for 6 to 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grape Extract</intervention_name>
    <description>Grape extract 100 mg twice daily for 6-8 weeks</description>
    <arm_group_label>Low Dose Combination</arm_group_label>
    <other_name>ShanStar Concord Grape</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pterostilbene 125 mg twice daily</intervention_name>
    <description>Pterostilbene 125 mg twice daily for 6-8 weeks</description>
    <arm_group_label>High Dose</arm_group_label>
    <other_name>pTeropure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years of age with a previous TC ≥200 mg/dL and/or a LDL ≥100 mg/dL on
             either no therapy or stable therapy

          -  Any concomitant cholesterol medication (not listed in the exclusion criteria) must be
             at a stable dose for at least 2 months prior to baseline laboratory

        Exclusion Criteria:

          -  Patients with significant hepatic, renal or gastrointestinal tract disease

          -  Receiving thiazolidinediones or fibric acid derivatives

          -  Current overt cardiovascular disease

          -  Women of reproductive potential not receiving birth control

          -  Pregnant/nursing women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Riche, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississsippi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hindawi.com/journals/jt/2013/463595/</url>
    <description>Riche DM, McEwen CL, Riche KD, Sherman JJ, Wofford MR, Deschamp D, Griswold M. Analysis of safety from a human clinical trial with pterostilbene. J Toxicol. 2013;2013:463595. doi: 10.1155/2013/463595. Epub 2013 Feb 4.</description>
  </link>
  <results_reference>
    <citation>Paul S, Rimando AM, Lee HJ, Ji Y, Reddy BS, Suh N. Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev Res (Phila). 2009 Jul;2(7):650-7. doi: 10.1158/1940-6207.CAPR-08-0224. Epub 2009 Jun 23.</citation>
    <PMID>19549798</PMID>
  </results_reference>
  <results_reference>
    <citation>Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem. 2004 Jul 28;52(15):4713-9.</citation>
    <PMID>15264904</PMID>
  </results_reference>
  <results_reference>
    <citation>Rimando AM, Nagmani R, Feller DR, Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agric Food Chem. 2005 May 4;53(9):3403-7.</citation>
    <PMID>15853379</PMID>
  </results_reference>
  <results_reference>
    <citation>Amarnath Satheesh M, Pari L. The antioxidant role of pterostilbene in streptozotocin-nicotinamide-induced type 2 diabetes mellitus in Wistar rats. J Pharm Pharmacol. 2006 Nov;58(11):1483-90.</citation>
    <PMID>17132211</PMID>
  </results_reference>
  <results_reference>
    <citation>Satheesh AM, Pari L. Effect of pterostilbene on lipids and lipid profiles in streptozotocin-nicotinamide induced type 2 diabetes mellitus. Journal of Applied Biomedine 6(1):31-37, 2008.</citation>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 2, 2013</lastchanged_date>
  <firstreceived_date>December 17, 2010</firstreceived_date>
  <firstreceived_results_date>March 19, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Riche</investigator_full_name>
    <investigator_title>Assistant Professor of Pharmacy Practice and Medicine</investigator_title>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Pterostilbene</keyword>
  <keyword>Blueberry</keyword>
  <keyword>Grape Extract</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Medical clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose</title>
          <description>Pterostilbene 125 mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>Low Dose</title>
          <description>Pterostilbene 50 mg twice daily</description>
        </group>
        <group group_id="P3">
          <title>Low Dose Combination</title>
          <description>Pterostilbene 50 mg/Grape Extract 100 mg twice daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Matching placebo twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose</title>
          <description>Pterostilbene 125 mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Low Dose</title>
          <description>Pterostilbene 50 mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Low Dose Combination</title>
          <description>Pterostilbene 50 mg/Grape Extract 100 mg twice daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Matching placebo twice daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="20"/>
                <measurement group_id="B5" value="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="17"/>
                <measurement group_id="B5" value="69"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="3"/>
                <measurement group_id="B5" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53.6" spread="11.2"/>
                <measurement group_id="B2" value="53.6" spread="7.9"/>
                <measurement group_id="B3" value="53.0" spread="13.7"/>
                <measurement group_id="B4" value="54.4" spread="11.9"/>
                <measurement group_id="B5" value="53.6" spread="11.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="13"/>
                <measurement group_id="B5" value="57"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="7"/>
                <measurement group_id="B5" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="20"/>
                <measurement group_id="B5" value="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Triglycerides</title>
        <description>Change in baseline triglycerides (TG)</description>
        <time_frame>Baseline and 6-8 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Pterostilbene 125 mg twice daily. Unadjusted change from baseline.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Pterostilbene 50 mg twice daily. Unadjusted change from baseline.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Combination</title>
            <description>Pterostilbene 50 mg/Grape Extract 100 mg twice daily. Unadjusted change from baseline.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo twice daily. Unadjusted change from baseline.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Triglycerides</title>
            <description>Change in baseline triglycerides (TG)</description>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14.6" lower_limit="-42.4" upper_limit="285.1"/>
                  <measurement group_id="O2" value="22.9" lower_limit="-48.6" upper_limit="157"/>
                  <measurement group_id="O3" value="14.4" lower_limit="-34" upper_limit="282.8"/>
                  <measurement group_id="O4" value="9.2" lower_limit="-59.4" upper_limit="67.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>Change in baseline systolic blood pressure and/or diastolic blood pressure</description>
        <time_frame>6-8 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Adverse Effects</title>
        <description>Number of participants with adverse effects as a measure of safety</description>
        <time_frame>Baseline and 6-8 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Pterostilbene 125 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Pterostilbene 50 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Combination</title>
            <description>Pterostilbene 50 mg/Grape Extract 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subjective Adverse Effects</title>
            <description>Number of participants with adverse effects as a measure of safety</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose</title>
          <description>Pterostilbene 125 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Low Dose</title>
          <description>Pterostilbene 50 mg twice daily</description>
        </group>
        <group group_id="E3">
          <title>Low Dose Combination</title>
          <description>Pterostilbene 50 mg/Grape Extract 100 mg twice daily</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Matching placebo twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Disclosure of the submitted materials approved per contractual agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Riche</name_or_title>
      <organization>University of Mississippi</organization>
      <phone>601-984-2640</phone>
      <email>driche@umc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
